FIG 2.
PLX5622 increases mortality and viral titer in WNV-infected mice. Mice were untreated or treated with PLX5622 for 14 days. Mice were them infected with WNV and monitored for 21 days. (A) PLX5622 treatment significantly increased mortality following infection with WNV (n = 12 animals per group). (B) Mouse body weight during infection was also monitored, and there was no significant difference between untreated and treated mice. (C) The viral titer in brains was found to be significantly increased in virus-infected, PLX5622-treated mice (gray bars) compared to infected controls (black bars) at 6 dpi (n = 11), 9 dpi (n = 9), and 10 dpi (n = 6). (D) Amounts of viral RNA in spleens were quantified by PCR and compared to a standard curve to determine genomic equivalent PFU. Error bars represent SEM. The dotted line represents our determined limit of accurate detection (102 PFU).